---
title: ReIrradiation With FDG-PET Guided Dose Painting
nct_id: NCT02921581
overall_status: COMPLETED
phase: NA
sponsor: Oslo University Hospital
study_type: INTERVENTIONAL
primary_condition: Head and Neck Cancer
countries: Norway
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02921581.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02921581"
ct_last_update_post_date: 2024-12-17
last_seen_at: "2026-05-12T06:30:03.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# ReIrradiation With FDG-PET Guided Dose Painting

**Official Title:** ReIrradiation With FDG-PET Guided Dose Painting for Recurrent and Second Primary Head and Neck Cancer

**NCT ID:** [NCT02921581](https://clinicaltrials.gov/study/NCT02921581)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** Oslo University Hospital
- **Collaborators:** Norwegian Cancer Society
- **Conditions:** Head and Neck Cancer
- **Start Date:** 2015-06
- **Completion Date:** 2023-08
- **CT.gov Last Update:** 2024-12-17

## Brief Summary

Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in intensity-modulated radiotherapy (IMRT) for primary head and neck cancer. This could also apply for recurrent and second primary head and neck cancers in previously irradiated volumes. This trial (RIDPAINT) investigates the feasibility of FDG-PET guided radiotherapy using IMRT dose-painting by contours for patients with recurrent and second primary head and neck cancer.

## Detailed Description

The standard re-irradiation regimen for head and neck cancer patients treated at the Oslo University Hospital is 1.5 Gy twice daily during 4 weeks with a total dose of 60 Gy.

In this study the radiotherapy is planned using 18F-FDG PET/CT making one experimental "dose-painting by contours" SIB (simultaneous integrated boost) plan with a maximum point dose of 75 Gy. The participants will be given 65 Gy and 70 Gy minimum doses to two GTVs inside the conventional GTV (60 Gy). GTV\_65Gy and GTV\_70Gy are determined from the SUV values from the 18F-FDG PET/CT according to the formula proposed by the Ghent group (Van der Straeten et al, R\&O -06). It is expected to keep the level of normal tissue side-effects within or slightly above the level of conventional radiotherapy (i.e. maximum dose of 60 Gy). In addition to the routine follow-up, the participants will be examined with 18F-FDG PET/CT 6 months after inclusion (4 1/2 months after end of radiotherapy) and HRQL measurements.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Histologically or cytologically verified invasive carcinoma of the head and neck region; ICD10: C01, C02.0 - C02.9; C03.0 - C03.9; C04.0 - C04.9; C05.0 - C05.9; C06.0 - C06.9; C09.0 - C09.9; C10.0 - C10.9; C11.0 - C11.9; C12; C13.0 - C13.9; C14.0 - C14.9; C30; C31.0 - C31.9; C32.0 - C32.9
* Planned treatment at the Norwegian Radium Hospital or at other participating university hospitals
* Age ≥18 years
* Ability to understand and respond to the questionnaires
* Informed consent received
* Squamous cell carcinoma in the head and neck region of patients previously irradiated for head and neck cancer
* No grade 3 or more late toxicity (except xerostomia) after the initial radio(chemo)therapy
* Minimal interval 12 months after the initial radio(chemo)therapy for primary head and neck cancer
* ECOG performance status ≤ 2

Exclusion Criteria:

* Patients planned for standard curative treatment (radical RT +/-concomitant chemotherapy or postoperative RT of primary disease)
* Patients who previously have been re-irradiated for overlapping second primary or relapse
* Other second primary tumors that are not under control
* Distant metastatic disease
```

## Interventions

- **FDG-PET guided dose painting** (RADIATION)

## Primary Outcomes

- **Number of participants accomplishing FDG-PET guided radiotherapy for recurrent and second primary head and neck cancer.** _(time frame: 1 month)_

## Secondary Outcomes

- **Locoregional control (at 6 months after inclusion) evaluated with PET/CT (according to RECIST).** _(time frame: 6 months)_
- **Number of participants with adverse events.** _(time frame: 3 years)_

## Locations (1)

- Oslo University Hospital, Oslo, Norway

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.oslo university hospital|oslo||norway` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02921581.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02921581*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*